RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase not stated

Registered title, quoted from ClinicalTrials.gov

Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Beijing Hospital; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Hospital北京医院BeijingHospital page
  2. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07773064, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 100 years; sex: all

    Registered eligibility fields

  2. Pregnancy, breastfeeding, or plans to become pregnant during the study period

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07773064, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Older than 18 years
  • Symptoms suggestive of myocardial ischemia or the presence of multiple cardiovascular disease risk factors
  • Underwent coronary angiography during hospitalization
  • Underwent blood sample collection during hospitalization
  • Underwent bilateral color fundus photography during hospitalization
  • Availability of complete clinical data

Exclusion Criteria:

  • History of heart transplantation or other solid-organ transplantation
  • Severe heart failure, defined as New York Heart Association (NYHA) functional class IV or left ventricular ejection fraction (LVEF) ≤20%
  • History of severe congenital heart disease, valvular heart disease, myocardial disease, pericardial disease, or aortic dissection
  • Pregnancy, breastfeeding, or plans to become pregnant during the study period
  • Progressive life-threatening disease
  • History of alcohol or drug abuse
  • Current treatment for a psychiatric disorder
  • Current receipt of radiotherapy or chemotherapy for a malignant tumor
  • Acute or chronic infectious disease
  • Severe hepatic insufficiency, renal insufficiency, thyroid disease and autoimmune disease
  • Life expectancy of less than 5 years
  • Ophthalmic diseases affecting the retinal vasculature or optic disc structure, including retinal artery occlusion, retinal vein occlusion, glaucoma, or congenital optic disc abnormalities
  • Color fundus photographs of insufficient quality because of severe ocular media opacity

Quoted from ClinicalTrials.gov, NCT07773064, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07773064, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07773064